During recent years, there has been remarkable progress with respect to the identification of molecular mechanisms and underlying pathology of neurodegenerative dementias. The latest evidence indicates that a common cause and pathological mechanism of diverse neurodegenerative dementias can be found in the increased production, misfolding, aggregation, and accumulation of specific proteins such as β-amyloid, tau protein, α-synuclein, prion protein, polyglutamine, transactive response DNA-binding protein (TARDBP or TDP-43), or fused in sarcoma (FUS). The conformational variants of these proteins range from small oligomers to the characteristic pathologic inclusions. However, it is noteworthy that a certain pathology can be a hallmark of a certain dementia, but there is a substantial overlap between different pathologies and different types of dementias. In this review, molecular mechanisms and pathologies of different neurodegenerative dementias will be summarized from the perspective of proteins rather than from the viewpoint of individual dementias. We will also review recent evidence surrounding these protein misfolding disorders, the role of toxic oligomers, cell-to-cell transmission, and the links between the misfolded proteins, along with the general therapeutic strategies for the protein misfolding disorders.
INTRODUCTION
In the last several years, noticeable progress has been made in regard to the identification of underlying molecular and In this review, we attempted to determine the roles of mis folded proteins in order to understand the pathologic origin of neurodegenerative dementias, and demonstrated the inter connectedness of misfolded proteins and neurodegenerative dementias.
General principles

1) The mechanisms of misfolding and aggregation
The canonical features of these neurodegenerative disor ders is that a specific protein can enfold into an alternative conformation which is stable, precipitates its aggregation, and is deposited in tissues in a fibrillar form [13] . These fibrillar deposits share similar morphological and tinctorial charac teristics with amyloids. In general, the naïve protein consists of αhelices and random coils, whereas the misfolded protein is composed of rich βstructures which are insoluble and im plicated in diseases [5, 6] . During misfolding and aggregation, a large conformational change in the proteins takes place, for ming a misfolded intermediate with exposed hydrophobic fragments. This intermediate has a tendency to aggregate and stabilize, giving rise to the formation of oligomers, protofibrils, fibrils, and finally aggregates or inclusions (Fig. 1) . The expo sure of hydrophobic sequences of the misfolded proteins to the surface is considered critical for protein aggregation [2, 3, 68] . The aggregation of proteins follows nucleationdepen dent polymerization, in which the critical event is oligomer formation that is soluble but serves as a nucleus to direct fur ther elongation of aggregates. This process is characterized by a slow lag phase which is followed by a rapid growth to form polymers [911] . An imbalance between production, aggre gation, and clearance of proteins brings about accumulation of misfolded proteins. In general, the accumulation of these misfolded proteins causes oxidative and neuroinflammatory damage leading to subsequent neurotransmitter, synaptic, and mitochondrial dysfunctions.
2) Selective neuronal vulnerability
The diverse phenotypes of different protein misfolding dis orders may come from the selective vulnerability of neurons or glial cells to the specific misfolded proteins. The relation ship between the phenotypes and the brain regions affected is more pronounced in the early stage of the diseases than in the later stages in which there are more extensive and diverse manifestations.
Postmortem analyses of human brains have revealed a char acteristic pathological pattern of the deposition of specific proteins. Aβ plaques appear first in the neocortex, followed by the allocortex and the subcortical structures in AD [12 15 ]. Tau pathologies first appear in the locus coeruleus and transentorhinal area including the entorhinal cortex, and then spread to the amygdala and interconnected neocortical areas in AD [15, 16] . The mutant polyglutamines also have their own specific groups of neurons showing selective vulnerabil ity to each protein in polyglutaminopathies [17] . Huntingtin (HTT) begins to appear in the striatum in HD. αSynuclein initially accumulates in the lower brainstem centers and as cends to the limbic and cortical association areas in PD [18, 19] , while in contrast, αsynuclein first appears in the cortex in DLB [20] . Although why different proteins are prone to accumulate in specific brain areas is still unknown, it has been speculated that local changes in expression or posttransla tional modifications of the specific proteins may account for the regional selectivity of early involvement [4] .
In addition to the regional selectivity, these protein deposits may have different pathological and clinical features, depend ing on whether the aggregates accumulate predominantly in neurons or in glial cells, or intracellularly or extracellularly ( 3) α-Synuclein and α-synucleinopathies αSynuclein is a 140residue neuronal protein which is found mostly in the neuronal presynaptic terminal in an un folded form under normal physiological conditions. This protein was first identified as the precursor protein for non amyloid constituents of senile plaques in AD [68] . It is pre sumed to support the regulation of the release of synaptic vesicles and the stabilization of soluble Nethylmaleimide sensitive factor attachment protein receptor (SNARE) family proteins including synaptobrevin2 and vesicleassociated 
4) Prion protein and prionopathies
PrP C (normal cellular prion protein isoform) is the natural prion protein encoded by the PRNP gene. PrP C is a glycopro tein which is expressed in the cells in the central nervous sys tem (CNS) and the immune system [77] . In the brain, the ex pression of PrP C is notably observed in neuronal synaptic membranes and is also expressed in astrocytes [78] . PrP C has been shown to be involved in signal transduction and to in teract with several intracellular signaling proteins [79] . Al though the understanding of the biologic functions of PrP C remains elusive, it is known to not be essential for cell surviv al [80] . However, the conversion of PrP C to the pathogenic PrP Sc (PrP scrapie) ends up resulting in neurodegeneration [81, 82] . PrP C acts as the raw material for conversion to PrP Sc [83] . Thus, these corrupted molecules easily selfaggregate and elicit neuronal injury. Although the exact mechanism of transmission remains uncertain, it is believed that prions can spread to other cells by synaptic transport [84] .
In humans, a variety of prion diseases (prionopathies or transmissible spongiform encephalopathies) are present, in cluding CJD, GSS, fatal familial insomnia, and kuru [83, 85] , although the diseases are uncommon. Prion diseases are uni que in that the same disease can have genetic, sporadic, and infectious (transmissible) origins and in that prion disease is the only infectious cerebral proteopathy [83, 84] . However, several studies implicated prionlike transmission of protein aggregates or inclusions in the initiation and spread of vari ous neurodegenerative disorders [84, 8690] .
5) Huntingtin and polyglutaminopathies
Huntingtin (HTT) is a cytoplasmic protein which is found to be associated with synaptic vesicles and microtubules. In [110, 111] . However, the causative relationship be tween TDP43 pathology and the mutation remains unclear at this time. 
7) Fused in sarcoma (FUS) and FUS proteinopathies
Links between proteins
Some of the protein misfolding diseases have more than one pathology, as some proteins are commonly found in more than one disease ( Table 2 ). The understanding of the interac tion between the misfolded proteins will help elucidate in part the complexity of the protein misfolding disorders.
1) β-amyloid (Aβ) and tau
Several experimental studies support that the accumula tion of Aβ precedes and trigger the aggregation of tau [120 123] , which is consistent with the amyloid cascade hypothe sis. Furthermore, Aβinduced neuronal dysfunction was pre vented by tau reduction [124] , and morphological analysis showed that taudepleted neurons revealed no evidence of degeneration in the presence of Aβ [125] . These results are supported by prior evidence that Aβ promotes the activation of glycogen synthase kinase3β (GSK3β) through the insulin 3) β-amyloid (Aβ) and prion protein
It has been reported that prion protein which Aβ binds is required for the impairment of synaptic plasticity mediated by Aβ oligomers [133] . It has also been found that the region of importance for the interaction between prion proteins and Aβ resides at the extreme aminoterminus of prion protein [134] . The role of prion protein in Aβinduced toxicity was confirmed by a recent study showing that prion protein is re quired for disrupting hippocampal synaptic plasticity by Aβ peptides [135] . Considering that oligomers are found around and within the amyloid plaques and are toxic to adjacent neurons [149 151 ], it has been suggested that inclusions serve as reservoirs for oligomers that can diffuse away from the inclusions and cause synaptic or neuronal toxicity [152] . The inclusions may initally sequester toxic soluble oligomers, but, eventually the reservoirs are overwhelmed and can no longer be protective.
4) α-Synuclein and tau
GWASs
Mass effect of the inclusions on surrounding neurons seems to be plausabe but it has been shown that senile plaques did not exert any mass lesion effects on neighboring cells [153] .
Nonetheless, whether it can be the case for other protein mis folding disoders needs to be further investigated.
2) Cell-to-cell disease transmission
Pathological similarities between prion diseases and AD suggest that the prionlike formation and seeding of protein aceous lesions may be involved in the pathogenesis of disease
The deposition of Aβ deposits were found in axonally in terconnected areas following the injection of Aβ aggregates into the brain, suggesting it spreads through neuronal path ways [157159] . The accumulation of abnormal tau starts in the entorhinal cortex (ERC) in the earliest stage of AD, and then spreads to the hippocampus followed by the neocortical regions [15] . However, it has been poorly explored whether tau pathology in the ERC initiates spreading to other struc tures, or that the pathology in the extrahippocampal areas begins independently. Using a transgenic mouse model ex pressing the pathological human tau protein primarily in the ERC, it has been demonstrated that tau pathology which be gan in the ERC spreads out from one neuron to other neu rons outside of the ERC across synapses [160] . This study re sult confirms observations from previous studies suggesting the transsynaptic celltocell spread hypothesis for AD [161, 162] .
αSynuclein pathology in PD starts in the anterior olfactory nucleus and the lower brainstem centers and ultimately as cends to the cortex [18, 19] . A recent study showed that puri fied αsynuclein fibrils are internalized into primary mouse hippocampal cells by endocytosis, recruit soluble endogenous αsynuclein, and promote the formation of insoluble Lewy bodies or neurites [163] . In this study, the aggregates of αsyn uclein appeared early in the axon terminals and later in the cell body, suggesting propagation along the axon and eventu ally to other cells. The report reinforces the earlier conclusions suggesting αsynuclein pathology from dying neurons is con veyed to neighboring neurons through celltocell transmis sion [19, 164, 165] , which is similar to the transmission of misfolded prion proteins in CJD [166] .
Furthermore, the prionlike celltocell transmission of the lesions has also been demonstrated in polyglutamine and TDP43 aggregates [167, 168] . However, the mode of cellto cell transmission for these proteins remains unclear.
General therapeutic strategies for protein misfolding disorders
Despite remarkable progress in the understanding of the 
